Research & Regulatory News

Comparing an Operation With an Injection

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Sabatella and colleagues published a network meta-analysis of randomised controlled trials comparing metabolic and bariatric surgery against GLP-1 receptor agonists in Obesity in April 2026. An indirect comparison, because the two are rarely randomised against each other.

Key facts

Study
Sabatella 2026 (PMID 41326176)
Journal
Obesity (Silver Spring), April 2026
Method
Network meta-analysis of RCTs
Comparison
Metabolic/bariatric surgery vs GLP-1 RAs
Why indirect
Direct randomisation is rare
Key limitation
Transitivity across dissimilar trials

Why the comparison is asked

Bariatric surgery has produced substantial and durable weight reduction for decades, with long-term outcome data no medicine can yet match. Incretin therapies now produce reductions approaching what surgery achieves. Whether an operation remains necessary is therefore a real clinical question rather than a rhetorical one.

Why randomising the two directly is rare

Blinding is impossible, recruitment is difficult because participants usually have a strong preference, and equipoise is hard to establish. A trial randomising someone to surgery or an injection asks them to accept an outcome they may find unacceptable, which is why so few such trials exist and why indirect methods are used instead.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What a network meta-analysis contributes here

It links surgical trials and drug trials through comparators they share, producing an indirect estimate with propagated uncertainty. That is more disciplined than reading the two literatures side by side, and it remains an indirect estimate resting on the assumption that the linked trials are comparable.

Why transitivity is strained in this particular comparison

Surgical trials and drug trials differ systematically. Surgical candidates typically have higher baseline BMI. Follow-up in surgical literature runs to years or decades where drug trials run to 68 or 72 weeks. Comparators differ. Those are the differences that make linking through a common arm questionable, and they should be examined rather than assumed away.

The dimension weight percentage does not capture

Durability and reversibility. Surgery is permanent and its effect persists without ongoing adherence; a medicine works while taken and weight returns when it stops. Two interventions producing the same percentage at one timepoint are not equivalent if one requires indefinite continuation and the other does not.

What this does not concern

Research material. This compares a surgical procedure with licensed medicines, both delivered under clinical supervision. Nothing supplied on this site is a GLP-1 receptor agonist, an alternative to surgery, or relevant to any treatment decision.

Frequently asked questions

Why not randomise surgery against a drug directly?

Blinding is impossible, participants usually have strong preferences, and equipoise is hard to establish, so few such trials exist.

What does the network method add?

It links surgical and drug trials through shared comparators with propagated uncertainty. More disciplined than reading the literatures side by side.

What does a weight percentage miss?

Durability and reversibility. Surgery persists without ongoing adherence; a medicine works while taken.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.